Veracyte CCO sells 2,539 shares at $35; holds 89,099 shares
Veracyte (VCYT) insider transaction: The company’s Chief Commercial Officer-CLIA reported a sale of 2,539 shares of common stock at $35 on 10/01/2025, coded “S”.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Veracyte (VCYT) insider transaction: The company’s Chief Commercial Officer-CLIA reported a sale of 2,539 shares of common stock at $35 on 10/01/2025, coded “S”. The filing notes the trades were made under a Rule 10b5-1 plan adopted on June 9, 2025. Following the transaction, the reporting person beneficially owns 89,099 shares, held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,539 | $35.00 | $89K |
Footnotes (1)
- F1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Veracyte (VCYT) disclose in this Form 4?
Was the sale under a Rule 10b5-1 plan?
What is the insider’s role at Veracyte (VCYT)?
What was the transaction code on the Form 4?
Is the ownership direct or indirect?
What security was involved in the transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.